IL-4R-alpha

Assets acting on this target.

Class
Anti-IL-4Ralpha monoclonal antibody
Notes
original target text: IL-4 receptor alpha

Interleukin-4 receptor alpha (IL-4Rα) is a cell-surface protein that serves as the shared signaling subunit for two related cytokines, interleukin-4 (IL-4) and interleukin-13 (IL-13). These cytokines are central drivers of what immunologists call type 2 inflammation, a branch of the immune response involved in defense against parasites but also implicated in allergic disease. By binding IL-4Rα, an antibody can block signaling from both cytokines simultaneously rather than neutralizing just one, which matters because IL-4 and IL-13 have overlapping but non-identical roles in promoting antibody class-switching to immunoglobulin E, recruitment of eosinophils, mucus overproduction, and tissue remodeling seen in allergic conditions. This dual-blockade rationale distinguishes IL-4Rα-targeting antibodies from agents that inhibit only IL-13 or only IL-4, since either cytokine alone can partially sustain the inflammatory pathway if the other is left unopposed. Conditions where this mechanism is broadly relevant include atopic dermatitis, asthma with an allergic or eosinophilic component, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis, all of which are driven substantially by type 2 immune signaling. Modulating this target is a strategy for reducing chronic allergic and eosinophilic inflammation across multiple organ systems by acting on a single upstream convergence point rather than on many downstream mediators individually.

By indication

IL-4R-alpha drugs compared

11 drugs, stage by indication
11 drugs acting on IL-4R-alpha: developer, modality, furthest stage and stage in each indication. Furthest stage first.
DrugDeveloperModalityFurthest stageStage by indication
dupilumabDupixentRegeneron Pharmaceuticals, Sanofimonoclonal antibodyApprovedApproved in Asthma; Approved in Atopic Dermatitis; Approved in Chronic Obstructive Pulmonary Disease; Approved in Chronic Spontaneous Urticaria; Approved in Eosinophilic Esophagitis; Approved in Prurigo Nodularis
GS101Jiangsu Genscend Biopharmaceuticalmonoclonal antibody (biosimilar)Phase 3Phase 3 in Atopic Dermatitis
ManfidokimabAkesomonoclonal antibodyPhase 3Phase 3 in Atopic Dermatitis
QL2108Qilu Pharmaceuticalmonoclonal antibody (biosimilar)Phase 3Phase 3 in Atopic Dermatitis
RademikibartConnect Biopharma, Simcere Pharmaceuticalmonoclonal antibodyPhase 3Phase 3 in Asthma; Phase 3 in Atopic Dermatitis; Phase 2 in Chronic Obstructive Pulmonary Disease
SHR-1819Jiangsu Hengrui Pharmaceuticalsmonoclonal antibodyPhase 3Phase 3 in Atopic Dermatitis
SSGJ-611Sunshine Guojian Pharmaceuticalmonoclonal antibodyPhase 3Phase 3 in Atopic Dermatitis
stapokibartAeira Pte. Ltd., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Keymed Biosciencesmonoclonal antibodyPhase 3Phase 3 in Atopic Dermatitis; Phase 3 in Prurigo Nodularis; Phase 2/3 in Asthma; Phase 2/3 in Chronic Obstructive Pulmonary Disease
TelikibartGenrix Biomonoclonal antibodyPhase 3Phase 3 in Atopic Dermatitis
APG808AbbVie, Apogee Therapeutics, Paragon Therapeuticsmonoclonal antibodyPhase 1Not recorded
CKD-706Chong Kun Dang Pharmaceuticalmonoclonal antibody (biosimilar)Phase 1Phase 1 in Atopic Dermatitis

← all mechanisms